Evidence map›Paper›PMID 14606955›Full record

ArticleThe Biochemical journal2004

Production and characterization of reduced NAADP (nicotinic acid-adenine dinucleotide phosphate).

Richard A Billington, Jan W Thuring, Stuart J Conway, Len Packman, Andrew B Holmes, Armando A Genazzani

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Enzymology of CaCells · 2023
    Review
  3. NAADP-Evoked CaHandbook of experimental pharmacology · 2023
    Article
  4. NAADP-Mediated CaHandbook of experimental pharmacology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. The NAADP receptor: commentary on Billington et al.British journal of pharmacology · 2004
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Richard A BillingtonDepartment of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, UK.
Jan W Thuring
Stuart J Conway
Len Packman
Andrew B Holmes
Armando A Genazzani
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pyridine nucleotide NAADP (nicotinic acid-adenine dinucleotide phosphate) has been shown to act as a Ca2+-releasing intracellular messenger in a wide variety of systems from invertebrates to mammals and has been implicated in a number of cellular processes. NAADP is structurally very similar to its precursor, the endogenous coenzyme NADP and while much is known about the reduced form of NADP, NADPH, it is not known whether NAADP can also exist in a reduced state. Here we report that NAADP can be reduced to NAADPH by endogenous cellular enzymes and that NAADPH is functionally inert at the NAADP receptor. These data suggest that NAADPH could represent a mechanism for rapidly inactivating NAADP in cells.

Indexed as

AnimalsCalciumCarrier ProteinsGlucosephosphate DehydrogenaseNADPOvumOxidation-ReductionSea UrchinsCalciumCarrier ProteinsGlucosephosphate DehydrogenaseNAADPNADP

Identifiers

PMID14606955
PMCPMC1223936
OpenAlexW2134244354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.